Utah Court of Appeals
Can a corporation rescind shares based on its own procedural failures? NexMed v. Mann Explained
Summary
NexMed sought to rescind 2.5 million shares (later reduced to 125,000 after a reverse split) that had been issued to Somerset Group in 1994 as compensation to Mann for his services in negotiating acquisition of a medical device patent. The trial court found the share issuance was valid and supported by adequate consideration.
Practice Areas & Topics
Analysis
In NexMed v. Mann, the Utah Court of Appeals addressed whether a corporation can rescind previously issued shares based on its own failure to properly document or authorize the issuance. The court’s decision provides important guidance for practitioners dealing with corporate governance disputes and share rescission claims.
Background and Facts
Mann acquired control of Target Capital (later renamed NexMed) and negotiated the acquisition of a herpes treatment device patent. As part of the transaction, Mann was to receive 2.5 million shares for his services in facilitating the patent acquisition. The shares were ultimately issued to Somerset Group, Mann’s company, through a board resolution in 1994. Six years later, NexMed’s board attempted to cancel and rescind these shares, claiming various procedural defects in the original issuance.
Key Legal Issues
The primary issues included whether Nevada corporate statutes required rescission due to alleged violations of board authorization requirements, whether Mann provided adequate consideration for the shares, and whether various evidentiary rulings by the trial court were proper. NexMed argued that procedural defects in the share issuance process mandated rescission under Nevada law.
Court’s Analysis and Holding
The Court of Appeals affirmed the trial court’s findings, holding that NexMed could not rescind the shares based on its own procedural failures. Applying correctness review to legal questions and clear error review to factual findings, the court determined that Mann provided adequate consideration through his services in negotiating the patent acquisition. The court rejected NexMed’s arguments under Nevada corporate statutes, finding that the statutes did not provide rescission as a remedy for the alleged procedural defects.
Practice Implications
This decision highlights the importance of focusing on substantive rather than procedural defects when challenging corporate share issuances. Practitioners should note that corporations cannot typically use their own failures in documentation or board authorization as grounds for later rescission, particularly when adequate consideration was provided. The case also demonstrates the courts’ reluctance to invalidate corporate transactions based solely on procedural irregularities when the underlying transaction was fair and supported by consideration.
Case Details
Case Name
NexMed v. Mann
Citation
2005 UT App 431
Court
Utah Court of Appeals
Case Number
No. 20040525-CA
Date Decided
October 14, 2005
Outcome
Affirmed
Holding
A corporation cannot rescind previously issued shares based on its own failure to properly authorize or document the issuance when the shares were issued for adequate consideration.
Standard of Review
Correctness for questions of law including contract interpretation and statutory interpretation; clear error for findings of fact; abuse of discretion for evidentiary rulings
Practice Tip
When challenging corporate share issuances, focus on substantive defects rather than the corporation’s own procedural failures in documentation or authorization.
Need Appellate Counsel?
Lotus Appellate Law handles appeals before the Utah Court of Appeals, Utah Supreme Court, California Court of Appeal, and the United States Court of Appeals for the Tenth Circuit.
Related Court Opinions
About these Decision Summaries
Lotus Appellate Law publishes these summaries to keep practitioners informed — not as legal advice. Each case turns on its own facts. If a decision here is relevant to your matter, we’re happy to discuss it.